[Effects of cicletanine on plasma lipid metabolism. Mid-term open trial in hypertensive patients with normal blood lipids and hyperlipidemia].
Cicletanine, an antihypertensive drug heralding a new pharmacological family, was tested in a short-term open trial on 39 hypertensive patients with normal or increased lipidemia according to the W.H.O. criteria. This trial confirmed that the drug has excellent antihypertensive activity (normalization of blood pressure in 71.8% of the cases), is very well tolerated and has no unfavourable effect on lipid metabolism.
Rouffy
J
J
Service de médecine interne et pathologie vasculaire, hôpital Saint-Louis, Paris.
Djian
F
F
Aubert
I
I
D000328:Adult; D000368:Aged; D004232:Diuretics / Q000009:adverse effects*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications / Q000378:metabolism; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000378:metabolism; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D011725:Pyridines; D013997:Time Factors
D004232:Diuretics; D011725:Pyridines; C038068:cicletanine
Effets du ciclétanine sur le métabolisme des lipides plasmatiques. Essai ouvert à moyen terme chez des hypertendus normo et hyperlipidémiques.